mainstay

Mainstay confirms its continued eligibility to the PEA-PME

on 30/01/2017 16:58

Mainstay Medical Applies for Approval to Market ReActiv8® in Australia

on 12/01/2017 16:53
Application for inclusion in Australian Register of Therapeutic Goods a key step towards commercialization of innovative treatment of Chronic Low Back Pain in Australian market
Read more

Mainstay Medical announces Half Year Financial Results

on 22/09/2016 10:33

ReActiv8-A Clinical Trial – Sustained Performance at One Year

on 20/09/2016 10:37
One-year data confirm clinically important, statistically significant, and lasting improvement in pain, disability and quality of life for people with Chronic Low Back Pain and limited treatment options
Read more

Mainstay Medical’s ReActiv8-B Clinical Trial for treatment of Chronic Low Back Pain enrols First Subject

on 14/09/2016 10:35
Trial to gather data in support of an application for US pre-market approval (PMA)
Read more